Abstract
Low-dose antihypertensive drugs in combination are prescribed frequently in clinical practice. Combination treatment is superior to monotherapy with higher doses of each drug in terms of blood pressure reduction and side effects. However, it is unclear whether combination treatment provides additional prognostic benefit beyond the blood pressure lowering effects. We assessed the usefulness of the combined treatment of a renin-angiotensin system inhibitor (RASI) and a calcium channel blocker (CCB) for all cardiovascular events in the Japanese Coronary Artery Disease (JCAD) Study population. In the JCAD Study, which is an observational and non-randomized trial, 13,812 patients with angiographically shown narrowing >50% in ≥1 of 3 major coronary arteries were followed up for a mean of 2.7 years. The primary endpoint of the study was all cardiovascular events. In the present study, baseline covariates possibly influencing the event rate were adjusted between the different treatment groups. There was no statistically significant difference in the event rate between the RASI monotherapy and combined treatment groups, although Kaplan-Meier analysis showed a 23% (p = 0.0003) relative risk reduction with an RASI monotherapy compared with the control group. In conclusion, there may be no additional benefit beyond blood pressure lowering effects in the combination of an RASI and a CCB in patients with angiographically documented CAD.
Similar content being viewed by others
References
Law MR, Wald NJ, Morris JK, Jordan RE (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 326:1427–1431
Neutel JM, Smith DHG, Weber MA (2001) Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 14:286–292
Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P (2009) Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 23:479–489
Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y (2008) Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels 23:91–95
Kuschair E, Acura E, Sevilla D (1996) Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 20 mg and placebo. Clin Ther 18:6–12
Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Böhm M, Nickenig G (2004) Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94:534–541
Zhang X, Hintze TH (1998) Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 97:576–580
Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y, Shin EK (2008) Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 140:73–81
The Japanese Coronary Artery Disease (JCAD) Study Investigators (2006) Current status of the background of patients with coronary artery disease in Japan: the Japanese Coronary Artery Disease Study (The JCAD Study). Circ J 70:1256–1262
D’Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281
Östergren J, Poulter NR, Sever PS, Dahlöf B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, for the ASCOT investigators (2008) The Anglo-Scandinavian cardiac outcomes trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens 26:2103–2111
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417–2428
Mourad JJ, Danchin N, Puel J, Gallois H, Msihid J, Safar ME, Tanaka H (2008) Cardiovascular impact of exercise and drug therapy in older hypertensives with coronary heart disease: PREHACOR study. Heart Vessels 23:20–25
Fujita M, Yamazaki T, Hayashi D, Kohro T, Okada Y, Nagai R, for The JCAD Study Investigators (2007) Comparison of cardiovascular events in patients with angiographically documented coronary narrowing with combined renin–angiotensin system inhibitor plus statin versus renin–angiotensin system inhibitor alone versus statin alone (from the Japanese Coronary Artery Disease Study). Am J Cardiol 100:1750–1753
Acknowledgments
This work was supported by a grant from the Japanese Circulation Foundation.
Conflict of interest
None for all authors.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Fujita, M., Sasayama, S., Terasaki, F. et al. Treatment effects of renin-angiotensin system inhibitor and calcium channel blocker in patients with coronary artery narrowing (from the Japanese Coronary Artery Disease Study). Heart Vessels 25, 453–459 (2010). https://doi.org/10.1007/s00380-010-0012-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00380-010-0012-5